Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Conditions
Androgenetic Alopecia (AGA) · Androgenetic Alopecia · AGA · Female Androgenetic Alopecia · Hair Loss
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Site 73, Birmingham, Alabama, United States
Site 89, Birmingham, Alabama, United States
Site 77, Phoenix, Arizona, United States
Site 30, Fort Smith, Arkansas, United States
Site 69, Encino, California, United States
Site 2, Fremont, California, United States
Site 64, Manhattan Beach, California, United States
Site 93, Northridge, California, United States
Site 66, Santa Monica, California, United States
Site 34, Sherman Oaks, California, United States
Site 94, Thousand Oaks, California, United States
Site 21, Vista, California, United States
Site 5, Castle Rock, Colorado, United States
Site 24, Greenwood Village, Colorado, United States
Site 17, Aventura, Florida, United States
Site 71, Boca Raton, Florida, United States
Site 86, Coral Gables, Florida, United States
Site 62, Coral Gables, Florida, United States
Site 99, Miami, Florida, United States
Site 54, Ocala, Florida, United States
Site 43, Atlanta, Georgia, United States
Site 90, Sandy Springs, Georgia, United States
Site 31, Boise, Idaho, United States
Site 61, Chicago, Illinois, United States
Site 53, Clarksville, Indiana, United States
Site 15, Indianapolis, Indiana, United States
Site 32, New Albany, Indiana, United States
Site 55, Plainfield, Indiana, United States
Site 27, West Lafayette, Indiana, United States
Site 79, Leawood, Kansas, United States
Site 52, Louisville, Kentucky, United States
Site 41, Baton Rouge, Louisiana, United States
Site 13, Covington, Louisiana, United States
Site 12, Metairie, Louisiana, United States
Site 75, New Orleans, Louisiana, United States
Site 84, Glenn Dale, Maryland, United States
Site 87, Rockville, Maryland, United States
Site 22, Brighton, Massachusetts, United States
Site 80, Chestnut Hill, Massachusetts, United States
Site 59, Quincy, Massachusetts, United States
Site 26, Clarkston, Michigan, United States
Site 68, Clinton Township, Michigan, United States
Site 83, Southfield, Michigan, United States
Site 98, Medina, Minnesota, United States
Site 56, Minneapolis, Minnesota, United States
Site 6, New Brighton, Minnesota, United States
Site 18, Hackensack, New Jersey, United States
Site 37, Kew Gardens, New York, United States
Site 97, New York, New York, United States
Site 82, Hickory, North Carolina, United States
Site 92, Huntersville, North Carolina, United States
Site 39, Boardman, Ohio, United States
Site 72, Cincinnati, Ohio, United States
Site 11, Columbus, Ohio, United States
Site 57, Portland, Oregon, United States
Site 60, Anderson, South Carolina, United States
Site 95, Hermitage, Tennessee, United States
Site 9, Knoxville, Tennessee, United States
Site 4, Nashville, Tennessee, United States
Site 76, Austin, Texas, United States
Site 74, College Station, Texas, United States
Site 67, Dallas, Texas, United States
Site 14, Houston, Texas, United States
Site 88, San Antonio, Texas, United States
Site 91, Sugar Land, Texas, United States
Site 19, South Jordan, Utah, United States
Site 29, Forest, Virginia, United States
Site 63, Norfolk, Virginia, United States
Site 85, Norfolk, Virginia, United States
Site 33, Burien, Washington, United States
Site 70, Mill Creek, Washington, United States
Study leads
Reid Waldman, M.D.
Study Chair
Veradermics, Inc.
Timothy Durso, M.D.
Study Chair
Veradermics, Inc.